nach oben

Erschienen in:

01.04.2012 | Case Report

A case of Behçet’s disease treated with a humanized anti-interleukin-6 receptor antibody, tocilizumab

verfasst von: Toru Hirano, Nobuyuki Ohguro, Satoshi Hohki, Keisuke Hagihara, Yoshihito Shima, Masashi Narazaki, Atsushi Ogata, Kazuyuki Yoshizaki, Atsushi Kumanogoh, Tadamitsu Kishimoto, Toshio Tanaka

Erschienen in: Modern Rheumatology | Ausgabe 2/2012

Einloggen, um Zugang zu erhalten

Abstract

A 47-year-old female patient with Behçet’s disease had been treated with colchicine, prednisolone, cyclosporine A, and infliximab. Because she relapsed, however, treatment with tocilizumab, a humanized anti-interleukin 6 receptor antibody, was started. This treatment suppressed the patient’s clinical manifestations, including ocular attacks, for 1 year and improved her visual acuity. This experience indicates that tocilizumab may constitute a therapeutic option for refractory Behçet’s disease.

Mendes D, Correia M, Barbedo M, Vaio T, Mota M. Behçet’s disease—a contemporary review. J Autoimmun. 2009;32:178–88.PubMedCrossRef

Fresko I, Yazici H. Treatment strategies for Behçet’s disease. Expert Opin Pharmacother. 2008;9:3211–9.PubMedCrossRef

Hatemi G, Silman A, Bang D, Bodaghi B, Chamberlain AM, Gul A, et al. EULAR recommendations for the management of Behçet disease. Ann Rheum Dis. 2008;67:1656–62.PubMedCrossRef

Ohno S, Nakamura S, Hori S, Shimakawa M, Kawashima H, Mochizuki M, et al. Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behçet’s disease with refractory uveoretinitis. J Rheumatol. 2004;31:1362–8.PubMed

Remmers EF, Cosan F, Kirino Y, Ombrello MJ, Abaci N, Satorius C, et al. Genome-wide association study identifies variants in the MHC class I, IL10, and IL23R/IL12RB2 regions associated with Behçet’s disease. Nat Genet. 2010;42:698–702.PubMedCrossRef

Mizuki N, Meguro A, Ota M, Ohno S, Shiota T, Kawagoe T, et al. Genome-wide association studies identify IL23R-IL12RB2 and IL10 as Behçet’s disease susceptibility loci. Nat Genet. 2010;42:703–6.PubMedCrossRef

Hamzaoui K, Hamzaoui A, Guemira F, Bessioud M, Hamza M, Ayed K. Cytokine profile in Behçet’s disease patients. Relationship with disease activity. Scand J Rheumatol. 2002;31:205–10.PubMedCrossRef

Hirohata S, Oka H, Mizushima Y. Streptococcal-related antigens stimulate production of IL6 and interferon-gamma by T cells from patients with Behçet’s disease. Cell Immunol. 1992;140:410–9.PubMedCrossRef

Mege JL, Dilsen N, Sanguedolce V, Gul A, Bongrand P, Roux H, et al. Overproduction of monocyte derived tumor necrosis factor alpha, interleukin (IL) 6, IL-8 and increased neutrophil superoxide generation in Behçet’s disease. A comparative study with familial Mediterranean fever and healthy subjects. J Rheumatol. 1993;20:1544–9.PubMed

10.

Wang CR, Chuang CY, Chen CY. Anticardiolipin antibodies and interleukin-6 in cerebrospinal fluid and blood of Chinese patients with neuro-Behçet’s syndrome. Clin Exp Rheumatol. 1992;10:599–602.PubMed

11.

Hirohata S, Isshi K, Oguchi H, Ohse T, Haraoka H, Takeuchi A, et al. Cerebrospinal fluid interleukin-6 in progressive neuro-Behçet’s syndrome. Clin Immunol Immunopathol. 1997;82:12–7.PubMedCrossRef

12.

Tanaka T, Ogata A, Narazaki M. Tocilizumab for the treatment of rheumatoid arthritis. Expert Rev Clin Immunol. 2010;6:843–54.PubMedCrossRef

13.

The classification criteria for Behçet’s disease. Japanese Ministry of Health and Welfare. 1987.

14.

Bhakta BB, Brennan P, James TE, Chamberlain MA, Noble BA, Silman AJ. Behçet’s disease: evaluation of a new instrument to measure clinical activity. Rheumatology. 1999;38:728–33.PubMedCrossRef

15.

Fukuhara S, Bito S, Green J, Hsiao A, Kurokawa K. Translation, adaptation, and validation of the SF-36 Health Survey for use in Japan. J Clin Epidemiol. 1998;51:1037–44.PubMedCrossRef

16.

Sfikakis N, Markomichelakis N, Alpsoy E, Assaad-Khalil S, Bodaghi B, Gul A, et al. Anti-TNF therapy in the management of Behçet’s disease—review and basis for recommendations. Rheumatology. 2007;46:736–41.PubMedCrossRef

17.

Kotter I, Zierhut M, Eckstein AK, Vonthein R, Ness T, Gunaydin I, et al. Human recombinant interferon alfa-2a for the treatment of Behçet’s disease with sight threatening posterior or panuveitis. Br J Ophthalmol. 2003;87:423–31.PubMedCrossRef

18.

Ohguro N, Yamanaka E, Otori Y, Saishin Y, Tano Y. Repeated intravitreal triamcinolone injections in Behçet’s disease that is resistant to conventional therapy: one-year results. Am J Ophthalmol. 2006;141:218–20.PubMedCrossRef

19.

Nishimoto N, Terao K, Mima T, Nakahara H, Takagi N, Kakehi T. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood. 2008;112:3959–64.PubMedCrossRef

20.

Tanaka T, Narazaki M, Kishimoto T. Anti-interleukin-6 receptor antibody, tocilizumab, for the treatment of autoimmune diseases. FEBS Lett (in press).

21.

Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, et al. Reciprocal developmental pathways for the generation of pathogenic effector Th17 and regulatory T cells. Nature. 2006;441:235–8.PubMedCrossRef

22.

Yoshimura T, Sonoda K, Ohguro N, Ohsugi Y, Ishibashi T, Cua DJ, et al. Involvement of Th17 cells and the effect of anti-IL-6 therapy in autoimmune uveitis. Rheumatology. 2009;48:347–54.PubMedCrossRef

23.

Hohki S, Ohguro N, Haruta H, Nakai K, Terabe F, Serada S, et al. Blockade of interleukin-6 signaling suppresses experimental autoimmune uveoretinitis by the inhibition of inflammatory Th17 responses. Exp Eye Res. 2010;91:162–70.PubMedCrossRef

24.

Haruta H, Ohguro N, Fujimoto M, Hohki S, Terabe F, Serada S, et al. Blockade of interleukin-6 signaling suppresses not only Th17 but also interphotoreceptor retinoid binding protein-specific Th1 by promoting regulatory T cells in experimental autoimmune uveoretinitis. Invest Opthalmol Vis Sci. 2011;52:3264–71.

Titel: A case of Behçet’s disease treated with a humanized anti-interleukin-6 receptor antibody, tocilizumab
verfasst von: Toru Hirano
Nobuyuki Ohguro
Satoshi Hohki
Keisuke Hagihara
Yoshihito Shima
Masashi Narazaki
Atsushi Ogata
Kazuyuki Yoshizaki
Atsushi Kumanogoh
Tadamitsu Kishimoto
Toshio Tanaka
Publikationsdatum: 01.04.2012
Verlag: Springer Japan
Erschienen in: Modern Rheumatology / Ausgabe 2/2012
Print ISSN: 1439-7595
Elektronische ISSN: 1439-7609
DOI: https://doi.org/10.1007/s10165-011-0497-5

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

A case of Behçet’s disease treated with a humanized anti-interleukin-6 receptor antibody, tocilizumab

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

15% bedauern gewählte Blasenkrebs-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Innere Medizin

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2012

Diffuse alveolar damage in patients with dermatomyositis: a six-case series

Necrotizing fasciitis in a patient with rheumatoid arthritis treated with tocilizumab

Frequency of fragmented QRS on ECG is increased in patients with rheumatoid arthritis without cardiovascular disease: a pilot study

Etanercept for the treatment of intractable hemophagocytic syndrome with systemic lupus erythematosus

Challenges to expanding the clinical application of musculoskeletal ultrasonography (MSUS) among rheumatologists: from a second survey in Japan

Regulation of osteoclast function

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

15% bedauern gewählte Blasenkrebs-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Innere Medizin